Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | terminated | Phase 1 | 5 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02883374 | Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety | unknown | Phase 2 | 30 | Dong meiOTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT01434394 |
| Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer(EAGLE) |
| completed |
| Phase 2 / Phase 3 |
| 243 |
| Shanghai Jiao Tong University School of MedicineOTHER |
| 1 |
| Aug 21, 2017 |
| clinicaltrials |
| NCT01542931 | TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 256 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00953420 | Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes(CADEN) | completed | Phase 2 | 20 | Baylor College of MedicineOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01326559 | Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 33 | Hong Kong Nasopharyngeal Cancer Study Group LimitedOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT03239769 | Compare the Aesthetic Effect of Different Thyroidectomies | completed | N/A | 120 | Peking University Cancer Hospital & InstituteOTHER | 0 | Aug 9, 2017 | clinicaltrials |
| NCT02114658 | Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients | completed | Phase 2 | 18 | BayerINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT00257335 | Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer | withdrawn | Phase 2 | 0 | Nilam RamsinghaniOTHER | 0 | Jul 31, 2017 | clinicaltrials |
| NCT01733823 | DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole | completed | Phase 1 / Phase 2 | 31 | Danish Head and Neck Cancer GroupNETWORK | 1 | Jul 28, 2017 | clinicaltrials |
| NCT02561533 | Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma | completed | N/A | 53 | University of AarhusOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT03213587 | Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | unknown | Phase 2 | 51 | Zhejiang Cancer HospitalOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT03210389 | A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT03196869 | the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer | unknown | Phase 2 | 128 | Guiyang Medical UniversityOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01392222 | Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others | completed | — | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT03158324 | Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 | unknown | Phase 2 | 52 | National University Hospital, SingaporeOTHER | 1 | Jun 15, 2017 | clinicaltrials |
| NCT01528163 | Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(RACATREX) | completed | Phase 2 | 101 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 2 | Jun 14, 2017 | clinicaltrials |
| NCT02662608 | Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) | completed | N/A | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02442661 | Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer | completed | — | 103 | University of Colorado, DenverOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT01303237 | A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck(PMS LAD SCCHN) | terminated | — | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT02593929 | Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | withdrawn | Early Phase 1 | 0 | University of PittsburghOTHER | 0 | Jun 8, 2017 | clinicaltrials |
| NCT01927887 | Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study | completed | N/A | 12 | Massachusetts General HospitalOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT03167385 | Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01874171 | Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC(De-ESCALaTE) | unknown | Phase 3 | 334 | University of WarwickOTHER | 3 | May 8, 2017 | clinicaltrials |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT01539655 | Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib(Vandetanib) | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02109250 | CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice(CaprelsaReg) | completed | — | 10 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02639858 | Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC | unknown | Phase 2 | 31 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 1, 2017 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT00095563 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00431210 | Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | completed | Phase 1 | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT03117257 | Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN | unknown | Phase 2 | 144 | Guiyang Medical UniversityOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 2 | Apr 14, 2017 | clinicaltrials |
| NCT00392665 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01865838 | A Study Into the Effect of Seprafilm in Open Total Thyroidectomy | terminated | N/A | 19 | National Cancer Centre, SingaporeOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT01256385 | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy(MAESTRO HN) | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Mar 27, 2017 | clinicaltrials |
| NCT01365208 | New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer | completed | — | 70 | Chinese University of Hong KongOTHER | 1 | Mar 24, 2017 | clinicaltrials |
| NCT03087695 | Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma | unknown | — | 200 | Taichung Veterans General HospitalOTHER | 1 | Mar 22, 2017 | clinicaltrials |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01534897 | Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 | completed | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT03071900 | CTC Detection Rate in SCCHN With a in Vivo Device | unknown | N/A | 50 | Nanjing Tongren HospitalOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00095628 | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2017 | clinicaltrials |
| NCT03068936 | IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma | unknown | Phase 3 | 716 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Mar 3, 2017 | clinicaltrials |
| NCT00513383 | Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT03058432 | Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 122 | Zhejiang Cancer HospitalOTHER | 1 | Feb 23, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 5, 2017source: clinicaltrials